BioSpace News Archive

Microsoft co-founder Paul Allen set aside $125 million to fund a new division at a scientific institute he founded to focus on understanding the immune system. This morning, it was reported that the Allen Institute is expanding.

Tremfya was being compared to Novartis’ Cosentyx (secukinumab) in a head-to-head study. In the trial, Tremfya showed that 84.5 percent of patients treated with the drug achieved at least 90 percent improvement in their baseline Psoriasis Area Severity Index (PASI) score at 48 weeks.

More pharma workers in France are receiving coal in their stockings this year after Germany-based Boehringer Ingelheim announced plans to cut about 300 jobs in that country as part of a reorganization of its operations in France.

Pfizer’s La Jolla cancer research center is set to grow by about 100 people. The pharma giant is transferring employees from a recently shuttered South San Francisco immunology site to bolster the work conducted near San Diego.

In September, Undercover Colors introduced the most comprehensive date rape drug detection device designed for personal use – thanks to its portability, small size, and ability to detect beverages spiked with drugs (commonly called roofies) in as little as 30 seconds

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the first patient was treated in a phase 1 dose escalation study combining pelareorep and carfilzomib with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo®(nivolumab) to treat relapsed multiple myeloma patients.

The International Society for Medical Publication Professionals (ISMPP) and the Pharma Collaboration for Transparent Medical Information (phactMITM) are pleased to announce their new partnership focused on enhancing the value of scientific communications through the collaboration of medical publication and medical information professionals.

Chad T. Lefteris, an executive with deep experience in integrated and academic health systems, was named chief operating officer for UCI Health, the patient-care organization of the University of California, Irvine

Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has completed patient randomization of its phase 2/3 clinical trial of MIN-102 for the treatment of adrenomyeloneuropathy (AMN). The trial enrolled adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD).

Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced an update of the ProSTAR study, its ongoing Phase 1b/2 clinical trial of CPI-1205 in patients with metastatic castration-resistant prostate cancer (mCRPC).